Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health Nurtec Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.490

    Clinical Policy: Rimegepant (Nurtec ODT)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.490 alerts

    Get alerted when Policy AZ.CP.PHAR.490 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Nurtec ODT for acute migraine treatment and episodic migraine prevention in adults for Arizona Complete Health commercial, HIM, and Medicaid members.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Rimegepant (Nurtec ODT)
    Policy CodePolicy AZ.CP.PHAR.490
    Change TypeModified
    Effective DateFeb 1, 2022
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that all applicable initial approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a new indication for episodic migraine prophylaxis.

    2FDA-approved covered uses
    75 mgMaximum dose
    8 ODTs/monthAcute quantity threshold
    4 migraine days/monthProphylaxis frequency
    Hypersensitivity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Contraindication

    Coverage Criteria

    Initial Therapy: Acute Migraine Treatment

    Covered for acute migraine treatment when ALL of the following are met:

    ALL of the following

    • Diagnosis of migraine headache
    • Member is age ≥ 18 years
    • Failure of at least TWO formulary 5HT1B/1D-agonist migraine medications (e.g., sumatriptan, rizatriptan, or zolmitriptan) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated. Prior authorization may be required.
    • For quantities ≤ 8 ODTs per month for treatment of acute migraine, failure of Ubrelvy unless contraindicated or clinically significant adverse effects are experienced
    • For dose-increase requests to quantities > 1 box of 8 ODTs per month, the member meets the migraine prophylaxis criteria below
    • Nurtec ODT is not prescribed concurrently with other CGRP inhibitors, including Aimovig, Ajovy, Emgality, Ubrelvy, or Vyepti
    • Dose does not exceed 75 mg (1 ODT) per day (one blister pack per month)

    Initial Therapy: Migraine Prophylaxis

    Covered for migraine prophylaxis when ALL of the following are met:

    ALL of the following

    • Diagnosis of episodic migraine
    • Member experiences ≥ 4 migraine days per month for at least 3 months≥ 4 migraine days/month for ≥ 3 months
    • Member does not have chronic migraine, defined as ≥ 15 headache days per month with ≥ 8 migraine days per month for at least 3 months
    • Prescribed by or in consultation with a neurologist, headache specialist, or pain specialist
    • Member is age ≥ 18 years

    Other Diagnoses and Indications

    Coverage for other diagnoses or indications follows ONE of the applicable pathways below:

    ANY of the following

    • Initial therapy pathway

      • If the diagnosis is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid
    • Continued therapy pathway

      • ONE of the following

        • Member is currently receiving the medication through a Centene benefit and documentation supports a positive response to therapy

          Approval duration: duration of request or 12 months, whichever is less

        • If the diagnosis is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety under the applicable off-label use policies (AZ.CP.PMN.53 for Arizona Medicaid) or evidence of coverage documents.

    Nurtec ODT must not be prescribed concurrently with Botox or other CGRP inhibitors. Applicable CGRP inhibitors include Aimovig, Ajovy, Emgality, Qulipta, Ubrelvy, and Vyepti. This exclusion applies to initial and continued therapy; acute migraine treatment also excludes concurrent use with CGRP inhibitors, and migraine prophylaxis specifically includes Botox.

    Nurtec ODT is contraindicated in members with a history of hypersensitivity reaction to rimegepant, Nurtec ODT, or any of its components. No boxed warnings are reported.

    Dosing, Frequency, and Utilization Parameters

    Acute-treatment quantity
    Monthly quantityNo more than 8 ODTs per month
    Acute-treatment dose75 mg (1 ODT) per day
    Ubrelvy requirementFailure of Ubrelvy is required unless contraindicated or clinically significant adverse effects are experienced
    Increased acute-treatment quantity
    Increased quantity thresholdMore than one box of 8 ODTs per month
    Prophylaxis criteriaThe member must meet the migraine prophylaxis criteria
    Continuation quantity

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Supporting Documentation

    Submit a prior authorization request with office chart notes, lab results, and other clinical documentation demonstrating that the member meets all applicable approval criteria for Nurtec ODT.

    • Include supporting documentation for acute migraine treatment, migraine prophylaxis, continuation therapy, or another covered indication, as applicable.
    Documentation Required

    Document Two Formulary Triptan Failures

    For acute migraine treatment, document failure of at least two formulary 5HT1B/1D-agonist migraine medications at up to maximally indicated doses, unless clinically significant adverse effects occurred or all are contraindicated.

    • Examples include sumatriptan, rizatriptan, and zolmitriptan.
    • Prior authorization may be required.

    Policy Background

    Rimegepant (Nurtec ODT) is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist. The policy covers its FDA-approved use for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults. For prevention, therapy may be considered when migraine attacks are frequent, including at least 4 migraine days per month, or when acute treatment is inadequate, contraindicated, overused, or associated with adverse effects.

    Definitions

    Chronic migraine
    Headache frequencyAt least 15 headache days per month
    Migraine frequencyAt least 8 migraine days per month
    Required durationAt least 3 months
    ODT
    AbbreviationODT
    MeaningOrally disintegrating tablet
    Product referenceNurtec is supplied as an orally disintegrating tablet

    Initial Therapy Criteria

    Acute Migraine Treatment: Initial Therapy

    Covered when ALL of the following are met.

    ALL criteria

    • The member has a diagnosis of migraine headache.
    • The member is at least 18 years old.
    • The member has failed at least two formulary 5-HT1B/1D-agonist migraine medications, such as sumatriptan, rizatriptan, or zolmitriptan, at up to maximally indicated doses, unless clinically significant adverse effects occurred or all are contraindicated.
    • For quantities of 8 ODTs or fewer per month, the member has failed Ubrelvy unless it is contraindicated or associated with clinically significant adverse effects.≤ 8 ODTs per month

    Continuation Criteria

    Continuation Therapy

    Continued therapy must meet the applicable criteria below.

    ONE applicable continuation pathway

    • Acute migraine treatment continuation

      • The member is currently receiving Nurtec ODT through the Centene benefit or previously met the initial approval criteria.
      • The member is responding positively to therapy.
      • For quantities of 8 ODTs or fewer per month, the member has failed Ubrelvy unless it is contraindicated or associated with clinically significant adverse effects.≤ 8 ODTs per month
      • If requesting more than one box per month

    Step Therapy Requirements

    StepRequired prior therapyTrial or failure requirement
    Step 1
    At least two formulary 5-HT1B/1D-agonist migraine medications, such as sumatriptan, rizatriptan, or zolmitriptan
    Failure at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated
    StepRequired prior therapyTrial or failure requirement
    Step 2
    Ubrelvy
    Failure for acute-treatment quantities of 8 ODTs or fewer per month, unless contraindicated or clinically significant adverse effects are experienced
    StepRequired prior therapyTrial or failure requirement
    Step 1
    Two oral migraine preventive therapies from different therapeutic classes, including antiepileptics, beta-blockers, or antidepressants
    Failure of each therapy after 8 weeks, unless clinically significant adverse effects are experienced or all are contraindicated
    StepRequired prior therapyTrial or failure requirement
    Step 2
    Two CGRP inhibitors used for migraine prophylaxis
    Failure of 3-month trials of both inhibitors, unless clinically significant adverse effects are experienced or all are contraindicated
    StepRequired prior therapyTrial or failure requirement
    Step 3
    Qulipta
    Failure at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced

    Quantity and Dose Limits

    Nurtec ODT acute-treatment quantity limit
    Strength75 mg
    Daily quantityOne ODT per day
    Monthly limitOne blister pack per month
    Nurtec ODT prophylaxis quantity limit
    Strength75 mg
    Dosing frequencyOne ODT every other day
    Monthly limitTwo blister packs per month
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Rimegepant (Nurtec ODT)
    Policy CodePolicy AZ.CP.PHAR.490
    Change TypeModified
    Effective DateFeb 1, 2022
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that all applicable initial approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaDosing, Frequency, and Utilization ParametersAuthorization, Documentation, and Denial RisksPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity and Dose Limits
    Failure of at least TWO oral migraine preventative therapies, each used for 8 weeks and from different therapeutic classes, unless clinically significant adverse effects are experienced or all are contraindicated: antiepileptic drugs (e.g., divalproex sodium, sodium valproate, or topiramate), beta-blockers (e.g., metoprolol, propranolol, or timolol), or antidepressants (e.g., amitriptyline or venlafaxine)
  1. Failure of 3-month trials of TWO CGRP inhibitors (e.g., Aimovig, Ajovy, or Emgality) used for migraine prophylaxis, unless clinically significant adverse effects are experienced or all are contraindicated. Prior authorization may be required; see Appendix B.
  2. Failure of Qulipta at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced
  3. Nurtec ODT is not prescribed concurrently with Botox or other CGRP inhibitors, including Aimovig, Ajovy, Emgality, Qulipta, Ubrelvy, or Vyepti
  4. Dose does not exceed 75 mg (1 ODT) every other day (two blister packs per month)
  5. An increased acute-treatment dose may be up to 75 mg (1 ODT) per day for 18 doses per month
    Episodic migraine frequency
    Minimum frequencyAt least 4 migraine days per month
    DurationThe frequency must be present for at least 3 months
    IndicationEpisodic migraine prophylaxis
    Chronic migraine exclusion
    Total headache daysAt least 15 headache days per month
    Migraine daysAt least 8 migraine days per month
    DurationThe pattern must be present for at least 3 months
    Acute-treatment dose
    Strength75 mg
    Daily regimenOne ODT per day
    Monthly supplyOne blister pack per month
    Prophylaxis dose
    Strength75 mg
    RegimenOne ODT every other day
    Monthly supplyTwo blister packs per month
    Frequent migraine attacks
    Frequency thresholdAt least 4 migraine headache days per month
    Clinical usePrevention should be considered for frequent attacks
    Guidance sourceAmerican Headache Society migraine guidance
    Regular acute-treatment use
    Treatment limitLimit acute treatment to an average of 2 headache days per week
    When exceededPatients exceeding this limit should be offered preventive treatment
    Clinical contextApplies to migraine patients who need acute treatments on a regular basis
    Acute-treatment overuse
    Overuse threshold10 or more days per month
    Included medication groupsErgot derivatives, triptans, opioids, combination analgesics, and mixed drug classes
    Preventive-treatment relevanceOveruse of acute treatments is an indication to consider preventive treatment
    Non-opioid analgesic overuse
    Overuse threshold15 or more days per month
    Included medication groupsNon-opioid analgesics, acetaminophen, and NSAIDs, including aspirin
    Preventive-treatment relevanceOveruse of acute treatments is an indication to consider preventive treatment
    Documentation Required

    Document Preventive Therapy Failures

    For migraine prophylaxis, document failure of the required preventive therapies before requesting Nurtec ODT, unless clinically significant adverse effects occurred or the therapies are contraindicated.

    • Document failure of two oral preventive therapies from different therapeutic classes, each used for 8 weeks.
    • Document failure of two CGRP inhibitors used for 3 months for migraine prophylaxis.
    • Document failure of Qulipta at up to maximally indicated doses.
    Note

    Six-Month Approval Duration

    The standard approval duration is six months when the applicable criteria are met.

    • Other provisions in the policy specify different durations for certain prophylaxis and continuation scenarios.
    Step Therapy

    Step Through Ubrelvy for Acute Treatment

    For acute-treatment quantities of eight ODTs or fewer per month, document failure of Ubrelvy unless it is contraindicated or caused clinically significant adverse effects.

    • This step-therapy requirement applies to acute migraine treatment quantities ≤8 ODTs per month.
    Step Therapy

    Step Through Oral Preventive Therapies

    For migraine prophylaxis, require trials of oral preventive therapies before Nurtec ODT, unless clinically significant adverse effects occurred or the therapies are contraindicated.

    • Use two therapies from different classes, each for at least 8 weeks.
    • Classes include antiepileptic drugs, beta-blockers, and antidepressants.

    Unsupported block type: step_therapyใാഴuput?

    Step Therapy

    Step Through Qulipta

    For migraine prophylaxis, document failure of Qulipta at up to maximally indicated doses unless it is contraindicated or caused clinically significant adverse effects.

    • Qulipta is required as a step before Nurtec ODT for prophylaxis.
    Documentation Required

    Required Clinical Documentation

    Provide clinical documentation supporting every applicable approval criterion, including diagnosis, age, treatment history, prescriber qualifications, dosing, quantity, and concurrent-therapy requirements.

    • Documentation may include office chart notes, lab results, medication history, and other clinical information.
    Documentation Required

    Prophylaxis Supporting Records

    For prophylaxis requests, submit records showing episodic migraine with at least four migraine days per month for at least three months, absence of chronic migraine, specialist involvement, and the required prior-therapy failures.

    • Document migraine frequency and duration.
    • Document the clinical assessment, including that chronic migraine is not present (≥15 headache days/month with ≥8 migraine days/month for at least three months).
    • Document prior oral preventive, CGRP inhibitor, and Qulipta therapy history, including durations, outcomes, adverse effects, or contraindications.
    Documentation Required

    Continuation Documentation

    For continuation requests, document the current approval or prior qualification, positive response to therapy, and continued compliance with all applicable criteria.

    • For migraine therapy, document current Centene-benefit use or that initial criteria were previously met.
    • For prophylaxis, document a maintained reduction in migraine days from baseline.
    • For dose increases, document the applicable quantity, dose, specialist involvement, and required prior-therapy history.
    Denial Risk

    Acute Migraine Criteria Not Met

    Acute migraine treatment is not approvable when the member does not meet all required acute-treatment criteria.

    • Diagnosis of migraine headache is required.
    • Member must be at least 18 years old.
    • Failure of two formulary 5HT1B/1D-agonists, or documented adverse effects or contraindications, is required.
    • For quantities ≤8 ODTs per month, Ubrelvy failure, adverse effects, or contraindication is required.
    • Nurtec ODT must not be used concurrently with other CGRP inhibitors.
    Denial Risk

    Prophylaxis Criteria Not Met

    Migraine prophylaxis is not approvable when the member does not meet all required prophylaxis criteria.

    • The member must have episodic migraine with at least four migraine days per month for at least three months and must not have chronic migraine.
    • The prescriber must be or consult with a neurologist, headache specialist, or pain specialist.
    • Required failures of two oral preventive therapies, two CGRP inhibitors, and Qulipta must be documented unless exceptions apply.
    • Nurtec ODT must not be used concurrently with Botox or other CGRP inhibitors.
    Denial Risk

    Excess Dose, Quantity, or Concurrent Therapy

    Coverage may be denied for dosing, quantity, or concurrent-therapy requests that exceed policy limits or combine Nurtec ODT with prohibited therapies.

    • Acute treatment: do not exceed 75 mg (one ODT) per day or one blister pack per month under the standard acute criterion.
    • Prophylaxis: do not exceed 75 mg every other day or two blister packs per month.
    • For acute dose increases, the new dose may not exceed 75 mg per day for 18 doses per month.
    • Do not prescribe concurrently with other CGRP inhibitors; prophylaxis also prohibits concurrent Botox.
    Denial Risk

    Unaddressed Non-FDA Indication

    For a non-FDA-approved indication not addressed by this policy, coverage requires sufficient documentation under the applicable off-label use policy or evidence of coverage documents.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53 when applicable.
    Denial Risk

    Hypersensitivity Contraindication

    Do not approve or administer Nurtec ODT when the member has a history of hypersensitivity to rimegepant, Nurtec ODT, or any component.

    • Hypersensitivity is a contraindication.
    Denial Risk

    Rimegepant or Nurtec ODT Hypersensitivity

    Specifically screen for and document hypersensitivity to rimegepant, Nurtec ODT, or its components before coverage or dispensing.

    • A history of hypersensitivity reaction precludes coverage.
    Denial Risk

    Acute Dose Exceeds 75 mg per 24 Hours

    For acute migraine treatment, a dose above 75 mg in any 24-hour period is outside the policy maximum and should not be approved.

    • Maximum acute dose: 75 mg (one ODT) per 24 hours.
    • The acute regimen is 75 mg orally as needed.
    CGRP antagonist
    ClassCGRP antagonist
    Full termCalcitonin gene-related peptide receptor antagonist
    Drug classificationRimegepant (Nurtec ODT) is a CGRP antagonist
  6. For a dose increase to more than one box of 8 ODTs per month, the member meets the migraine prophylaxis criteria.> 1 box of 8 ODTs per month
  7. Nurtec ODT is not prescribed concurrently with another CGRP inhibitor.
  8. The dose does not exceed 75 mg (1 ODT) per day.75 mg (1 ODT) per day

    One blister pack per month.

  9. Migraine Prophylaxis: Initial Therapy

    Covered when ALL of the following are met.

    ALL criteria

    • The member has a diagnosis of episodic migraine.
    • The member experiences at least 4 migraine days per month for at least 3 months.≥ 4 migraine days per month for ≥ 3 months
    • The member does not have chronic migraine, defined as at least 15 headache days per month with at least 8 migraine days per month for at least 3 months.Chronic migraine: ≥ 15 headache days/month with ≥ 8 migraine days/month for ≥ 3 months
    • The medication is prescribed by or in consultation with a neurologist, headache specialist, or pain specialist.
    • The member is at least 18 years old.
    • The member has failed at least two oral migraine preventive therapies from different therapeutic classes, each used for 8 weeks, unless clinically significant adverse effects occurred or all are contraindicated.
    • The member has failed 3-month trials of two CGRP inhibitors used for migraine prophylaxis, unless clinically significant adverse effects occurred or all are contraindicated.
    • The member has failed Qulipta at up to maximally indicated doses unless it is contraindicated or associated with clinically significant adverse effects.
    • Nurtec ODT is not prescribed concurrently with Botox or another CGRP inhibitor.
    • The dose does not exceed 75 mg (1 ODT) every other day.75 mg (1 ODT) every other day

      Two blister packs per month.

  10. The member has failed at least two oral migraine prophylactic therapies from different therapeutic classes, each for 8 weeks, unless clinically significant adverse effects occurred or all are contraindicated.
  11. The member has failed 3-month trials of two CGRP inhibitors used for migraine prophylaxis, unless clinically significant adverse effects occurred or all are contraindicated.
  12. The member is being treated by or in consultation with a neurologist or headache or pain specialist.
  13. The new dose does not exceed 75 mg (1 ODT) per day for 18 doses per month.75 mg per day for 18 doses per month
  14. Migraine prophylaxis continuation

    • The member is currently receiving Nurtec ODT through the Centene benefit or previously met the initial approval criteria.
    • The member has experienced and maintained a positive response to therapy, evidenced by a reduction in migraine days per month from baseline.
    • Nurtec ODT is not prescribed concurrently with Botox or another CGRP inhibitor.
    • If requesting a dose increase, the new dose does not exceed 75 mg (1 ODT) every other day.75 mg (1 ODT) every other day

      Two blister packs per month.

  15. Nurtec ODT increased acute-treatment quantity
    Strength75 mg
    Daily dosing limit75 mg per day
    Monthly quantity18 doses per month
    Rimegepant/Nurtec ODT maximum dose
    Maximum dose75 mg
    Acute-treatment intervalThe maximum dose in a 24-hour period is 75 mg
    Prophylaxis maximum75 mg per dose